SEP 30, 2018 08:17 PM PDT

Researchers Re-classify the 'Magic Mushroom' Drug

WRITTEN BY: Nouran Amin

Credit: © aquatarkus / Fotolia via Science Daily

Researchers at John Hopkins have evaluated the safety and efficacy of compound, psilocybin, found in hallucinogenic mushrooms. They suggested that if evaluations pass phase III clinical trials then psilocybin should be re-categorized from a schedule I drug to a schedule IV drug. The findings were published in Neuropharmacology. "We want to initiate the conversation now as to how to classify psilocybin to facilitate its path to the clinic and minimize logistical hurdles in the future," explains Matthew W. Johnson, Ph.D., associate professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine. "We expect these final clearance trials to take place in the next five years or so."

According to the Controlled Substances Act of 1970, any compound that has the potential for abuse is placed based on the criteria that take into the account whether the drug has accepted medical use as well as its safety and the potential for abuse. Even though preliminary research studies suggest that psilocybin may be good for smoking cessation and for disorders such as cancer-specific depression and anxiety, it must clear phase III clinical trials before the Food and Drug Administration can be petitioned to reclassify it.

Research on animals and humans have shown that psilocybin holds low potential for abuse, the researchers say. "We should be clear that psilocybin is not without risks of harm, which are greater in recreational than medical settings, but relatively speaking, looking at other drugs both legal and illegal, it comes off as being the least harmful in different surveys and across different countries," says Johnson.

Additionally, psilocybin also is lowest in the potential for causing lethal overdose. However, that does not mean that psilocybin is less harmful than other drugs and not prone to compulsive abuse. "We believe that the conditions should be tightly controlled and that when taken for a clinical reason, it should be administered in a healthcare setting monitored by a person trained for that situation," says Johnson.

Watch this video to learn more about magic mushrooms:

Source: John Hopkins School of Medicine

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 09, 2018
Drug Discovery
OCT 09, 2018
'Copper Antibiotic Peptide' Effective in Eradicating Tuberculosis
The bacterium responsible for Tuberculosis has found a way to avoid antibiotics by hiding inside the macrophages which are the specific immune cells that a...
OCT 18, 2018
Drug Discovery
OCT 18, 2018
Potential Drug Target for Tactile Allodynia
According to research published in the journal Science Translational Medicine in collaboration with a study led by the National Institutes of Health, a new...
NOV 29, 2018
Cannabis Sciences
NOV 29, 2018
Want to Smoke Weed? For Science?
Clinical trials are a necessary part of the drug approval process. All drugs on the market, even the over-the-counter drugs, have gone through clinical tri...
DEC 23, 2018
Drug Discovery
DEC 23, 2018
Buruli ulcer: promising drug for a forgotten disease
One of the most forgotten and neglected diseases is Buruli ulcer, a debilitating and stigmatized condition affecting primarily children in West and Central...
JAN 16, 2019
Genetics & Genomics
JAN 16, 2019
Gene Therapy for a Leading Cause of Infant Death is Closer to Market
New treatments for some diseases can have extremely high price tags. One example is Zolgensma, which might cost $5 million per patient....
JAN 23, 2019
Cardiology
JAN 23, 2019
New Discoveries Bring Us Closer To Eliminating Heart Attacks
A host of new discoveries bring medicine closer to the goal of ending heart attacks. These include new protective methods that can help identify those at r...
Loading Comments...